The Merck-Terns Deal: Shaping the Future of Oncology M&A 1 source

Merck is nearing a $6 billion acquisition of Terns Pharma to bolster its oncology portfolio ahead of Keytruda's patent expiry. This deal signals potential aggressive spending by large drugmakers on cancer assets, creating opportunities for takeover targets and oncology-focused…

Listen